The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Merck and Daiichi Sankyo announced. Oncternal Therapeutics announced termination of a clinical trial of the androgen receptor inhibitor ONCT-534 in metastatic castration resistant prostate cancer and ...

BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving adjuvant immunotherapy alongside chemotherapy ...

Axial Spondyloarthritis (axSpA) is a form of arthritis that mainly causes discomfort and inflammation in the spine and ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

So KEYNOTE-189, whether it's for them, so anyone that's trying to develop combinations of bispecific or if it's us using KEYTRUDA with one of the ADCs that we partnered with, whether it's Kulun or ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Artificial heart maker Carmat on Wednesday announced the launch of a new capital increase for an initial amount of 10.3 ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...